JPMorgan analyst Richard Vosser downgraded GSK to Underweight from Neutral with a price target of 1,350 GBp, down from 1,600 GBp. The analyst continues to see a "bifurcation" in European pharma company outlooks in 2023, both in terms of pipeline readouts and longer-term where "genericisations again need to be navigated." As such, he would avoid companies like GSK and Roche, seeing downside to 2023 consensus estimates and "potentially challenged" 2025-2030 outlooks. Vosser continues to favor companies "which have sustainably higher growth" and "far more" pipeline data points, new launches to drive estimate upgrades.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK:
- Barclays views GSK acquisition interest as positive for oncology stocks
- GSK seeks under-appreciated biotechs ‘hiding in plain sight’, FT reports
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron’s says
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
